Amarin Corporation (AMRN) short term trade and lonAmarin Corporation (AMRN) short term trade and long term option ideas.
Short term trade ideas -
www.biotechnologyevents.com/node/3845
Option strategies -
www.biotechnologyevents.com/node/3844
It is our opinion that the FDA regulatory decision, PDUFA date July 26, 2012, for AMR-101 is a "binary event" for Amarin (AMRN).
AMR-101 is Amarin's only clinical stage program. The regulatory approval of AMR-101 will pave the way for Amarin to become a commercial stage biotechnology company and increase the likelihood that the company will sign partnership agreements or be acquired.
A negative outcome would delay or negate these possible achievements.
The possibility that Amarin will partner AMR-101 in one or more territories including the US and EU or that the company will be acquired is in our opinion very high considering the efficacy, differentiating profile (AMR-101 lowers LDLc levels verses competitor compounds), safety and market opportunities for AMR-101.
Any news flow around one of these possibilities should move the share price considerably higher.
It is our opinion that these pending events will sustain interest in the company's shares. The technical indicators we follow have become favorable for AMRN and indicate a short term trade opportunity.
We have trade ideas and daily analysis available for AMRN and many other biotech stocks at BiotechnologyEvents.com.
Follow our Short Term Trading Strategies/daily analysis and our Option Trading Strategies by clicking on their respective links under the Featured Content section found on our home page.
www.biotechnologyevents.com/
As always, it is free of charge.
Very best
J